在与BRCA1相关的三阴性乳腺瘤中评估药物疗效的MicroRNA空间分析
bioRxiv : the preprint server for biology
|February 6, 2026
概括
在BRCA1/2突变乳腺癌中,PARP抑制剂耐药性可以通过组合疗法克服. 空间微RNA分析预测了耐药性,为治疗策略提供了一个新的生物标志物.
科学领域:
- 在瘤学瘤学.
- 遗传学 遗传学 是一个
- 生物标志物发现发现
背景情况:
- 在乳腺癌中,BRCA1/2突变导致同源重组缺陷 (HRD),这些乳腺癌最初对PARP抑制剂敏感.
- 高率 (40-70%) 的PARP抑制剂耐药性发展,需要新的治疗策略和预测生物标志物.
研究的目的:
- 研究克服BRCA1/2-突变乳腺癌中PARP抑制剂耐药性的方法.
- 探索空间微RNA (miRNA) 分析作为预测治疗反应的预后工具.
主要方法:
- 使用了K14-Cre Brca1f/f Trp53f/f 鼠标模型,并获得了PARP电阻.
- 在体内评估PARP抑制剂与PI3K抑制或PolyI:C的组合.
- 在使用纳米升井阵列的FFPE段落上应用空间miRNA分析,并开发了整合LDA和PCA的分析框架.
主要成果:
- 与单一治疗相比,两种PARP抑制剂组合都显示出较好的抗瘤活性.
- 空间miRNA分析框架成功地将瘤分层为对PARP抑制剂敏感或耐药.
- 综合免疫架构分析揭示了免疫透和miRNA表达模式的共同定位.
结论:
- 组合疗法在克服PARP抑制剂耐药性方面表现有前途.
- 空间miRNA分析是一个可行的预后工具,用于预测BRCA1/2-突变乳腺癌的耐药性.
- 这种方法提供了一个潜在的生物标志物来指导治疗决策.
相关概念视频
MicroRNAs
24.2K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
24.2K
MicroRNAs
4.0K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
4.0K
Drug Dissolution: Requirements and Profile Comparison
282
The acceptance criteria for dissolution profile data are anchored in Q values, representing the percentage of drug dissolved within a specified period. This assessment unfolds in three stages:First Stage: The test passes if all six drug dosage units are equal to or greater than Q plus 5%; otherwise, the sample proceeds to the second stage.Second Stage: The average of twelve units must be equal to or greater than Q, with no unit falling below Q - 15% to pass; if not, it progresses to the final...
282
Self-Efficacy
233
Self-efficacy is the belief in one's capacity to organize and execute actions necessary to manage prospective situations. This belief significantly influences how individuals approach goals, tasks, and challenges across different domains of life.Psychological and Educational ImpactsIndividuals with strong self-efficacy are more resilient in the face of difficulties. They are more likely to adopt effective problem-solving strategies, persist through obstacles, and regulate emotions such as...
233
Scalar and Vector Triple Products
4.5K
Two vectors can be multiplied using a scalar product or a vector product. The resultant of a scalar product is scalar, while with vector products, the resultant is a vector. These rules of the scalar or vector product between two vectors can be applied to multiple vectors to obtain meaningful combinations. The scalar triple product is the dot product of a vector with the cross product of two vectors.
The scalar triple product is the dot product of a vector with the cross product of two vectors....
The scalar triple product is the dot product of a vector with the cross product of two vectors....
4.5K
Negative Regulator Molecules
38.5K
Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
38.5K


